Asthma control data
of patients aged 12+ years experienced
AS MEASURED BY ACQ‑5,
with DUPIXENT 200 mg Q2W +
SOC vs 67% with placebo +
SOC (OR: 1.46
[95% CI: 0.90,
2.35]) (baseline blood EOS
≥300 cells/μL, QUEST)1,a,b
- 71% of patients improved their asthma control with DUPIXENT 300 mg Q2W + SOC vs 64% with placebo + SOC
(OR: 1.39 [95% CI: 0.88, 2.19]) (baseline blood EOS ≥300 cells/µL, QUEST)
ACQ-5: Asthma Control Questionnaire, 5-item version, a patient-reported measure of asthma control. Higher scores indicate less
asthma control; a global score is calculated ranging from 0 to 6. The minimum clinically important difference is 0.5.1,2
Quality of life data
of patients aged 12+ years experienced an
AS MEASURED BY AQLQ(S),
with DUPIXENT 200 mg Q2W +
SOC vs 55% with placebo +
SOC (OR:
2.02 [95% CI: 1.24,
3.32]) (baseline blood EOS
≥300 cells/μL, QUEST)
- 65% of patients experienced an improved quality of life with DUPIXENT 300 mg Q2W + SOC vs 55% with placebo + SOC
(OR: 1.79 [95% CI: 1.13, 2.85]) (baseline blood EOS ≥300 cells/µL, QUEST)
AQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The minimum clinically important difference is 0.5.1,2
aResponder rates at Week 52 in QUEST were assessed as secondary endpoints and defined as an improvement in score of 0.5 or more (scale ranged from 0 to 6 for ACQ-5 and 1 to 7 for AQLQ[S]).1
bACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred.2
EOS, eosinophils; OR, odds ratio; Q2W, once every 2 weeks; QoL, quality of life; SOC, standard of care.
Not an actual DUPIXENT patient.